Viking Therapeutics’ oral GLP-1 pill, VK2735, is making significant strides in the competitive landscape of obesity treatments, offering a promising alternative to injectable therapies. This clinical-stage biopharmaceutical company is actively developing an experimental oral drug, VK2735, designed to treat obesity and various other metabolic disorders. The drug’s innovative mechanism as a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors has shown considerable potential in weight management, sparking both optimism and scrutiny within the financial and medical communities.
Unpacking VK2735’s Clinical Performance
Viking Therapeutics has meticulously advanced VK2735 through a series of clinical trials, revealing both its strengths and the challenges in a highly competitive market. The journey began with a Phase 1 Multiple Ascending Dose (MAD) trial between 2022 and 2023, which established VK2735’s safety and tolerability. Crucially, this early phase demonstrated a mean weight loss of up to 18 pounds over just 28 days in healthy obese volunteers, setting an encouraging precedent for further development.
Building on these initial successes, the Phase 2 VENTURE-Oral Dosing trial (NCT06068946), initiated in September 2023, evaluated once-daily oral VK2735 in adults with obesity or overweight and at least one weight-related comorbidity. The study successfully achieved its primary endpoint, showing statistically significant reductions in body weight compared to placebo. Participants experienced up to a 12.2% mean body weight reduction from baseline at 13 weeks. While an earlier Phase 2 trial for the subcutaneous formulation achieved a higher 14.7% mean weight loss over the same period, the oral formulation’s results are still noteworthy. Responder rates were particularly strong, with up to 97% of participants achieving at least 5% weight loss and up to 80% achieving at least 10% weight loss, significantly outperforming the placebo group.
Viking Therapeutics’ Oral GLP-1 Pill in a Crowded Market
The obesity drug market is experiencing rapid expansion, with GLP-1 receptor agonists leading the charge. While injectable market leaders like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have set high benchmarks, the demand for convenient oral alternatives is immense. However, Viking Therapeutics’ oral GLP-1 pill faces stiff competition. For instance, Novo Nordisk’s oral Wegovy (semaglutide) demonstrated 13.6% weight loss after 64 weeks in the OASIS4 trial, and Eli Lilly’s orforglipron achieved an average of 6-8% body weight loss in patients with diabetes in a Phase 3 trial. The efficacy of VK2735 in the Phase 2 VENTURE-Oral Dosing trial, at up to 12.2% mean body weight loss over 13 weeks, was lower than these established and emerging competitors.
This comparative performance led to a significant 42% drop in Viking’s stock on August 19, 2025, despite meeting its primary endpoint. Experts generally believe that oral formulations are unlikely to surpass the efficacy of injectable formats in terms of maximum weight loss. Yet, the convenience factor of a pill could attract a substantial patient population resistant to injections, potentially carving out a unique market niche for Viking. Viking’s CEO, Brian Lian, Ph.D., remains optimistic, highlighting the progressive nature of weight loss observed in trials and the potential for greater reductions with longer dosing periods. The company plans to advance oral VK2735 into late-stage studies in Q3 2026, with data for the subcutaneous formulation expected in 2027. Investors keen on related Finance news will be watching these developments closely.
“The progressive nature of weight loss observed in our trials, coupled with the potential for increased efficacy over longer dosing periods, positions VK2735 as a significant contender in the oral obesity market,” stated Brian Lian, CEO of Viking Therapeutics, emphasizing the drug’s long-term potential.
The Road Ahead for VK2735
Viking Therapeutics is not resting on its laurels. Beyond the current trial results, the company is actively exploring a maintenance dosing strategy for VK2735, aiming to sustain weight loss over extended periods. The announcement of positive top-line results from the Phase 2 VENTURE trial in the first quarter of 2024, followed by the publication of these results in *Obesity* on January 12, 2026, underscores the company’s commitment to scientific rigor and transparency. With the Phase 2 VENTURE-Oral Dosing trial results announced on August 19, 2025, and plans to advance into Phase 3 trials in Q3 2026, Viking Therapeutics is clearly committed to bringing this oral GLP-1 pill to market. The journey ahead involves navigating regulatory hurdles and further demonstrating a compelling risk-benefit profile to secure a strong position in the lucrative obesity treatment sector.
In conclusion, while Viking Therapeutics’ oral GLP-1 pill, VK2735, has shown promising results and a strong safety profile, its path to market leadership will depend on its ability to differentiate itself in terms of long-term efficacy, tolerability, and patient convenience against established and emerging competitors. The company’s strategic focus on both oral and subcutaneous formulations, coupled with an optimistic outlook from its leadership, suggests a determined effort to capture a significant share of the evolving metabolic disorder treatment market.
